Check out your Company Bowl for anonymous work chats.
Grifols is proud to celebrate International Plasma Awareness Week. We appreciate the kindness and generosity of plasma donors everywhere for helping to save patients’ lives. To learn more about the importance of plasma donation, visit http://glassdoor.com/slink.htm?key=vMRg8 #plasmaprotein #IPAW2019
There are nearly 50 million people living with dementia worldwide. Two out of every three cases are caused by Alzheimer's disease, which, despite significant research and investment, remains incurable. Awareness and understanding are necessary to end with the misconceptions that surround Alzheimer’s. Let's all continue working to defeat this disease. #WorldAlzheimersDay #alzheimersawareness #alzheimersdisease #GrifolsAMBAR
Grifols continues to deliver strong financial performance, reporting revenue growth of 14.3% to 2.4 billion euros in the first half of 2019.
Grifols continues to release positive data that reinforce the efficacy of AMBAR, the company’s breakthrough clinical study to treat Alzheimer’s Disease. http://glassdoor.com/slink.htm?key=vMtU2
Grifols continues to deliver on its commitment to sustainability in key areas such as energy optimization, reduction in consumption and preventing and reducing waste. We keep working to ensure our operations are as efficient and respectful of the environment as possible.
Grifols publishes its 2018 CSR report, an in-depth review of the company’s social, environmental and economic achievements. The report highlights Grifols’ firm commitment and pledge of transparency to stakeholders such as donors, patients, medical professionals, employees and society as a whole. http://glassdoor.com/slink.htm?key=vMdJw
► Grifols continues to expand its plasma donation center network in the US The additional 26 plasma donation centers acquired from Interstate Blood Bank Inc. further solidify Grifols’ global leadership position in plasma collection and plasma-derived therapies. Our 286 centers in the U.S. and Europe provide the plasma we use to meet the growing demand for our medicines to treat chronic, rare and life-threatening diseases.
Grifols plans to attend two major Bay Area networking events this week: BioSpace Biotech Bay on 4/29 and the University of California Alumni fair on 5/2. As a company committed to people, we are always looking for talent that will continue to diversify our team. Click here to learn more about what it means to join the Grifols family: http://glassdoor.com/slink.htm?key=vMvph
We’ve begun processing the first batch of plasma from survivors of Ebola—the culmination of an agreement with the Republic of Liberia to produce anti-Ebola immunoglobulin in the context of a clinical research program to combat the virus. This innovative initiative has the potential to revolutionize the way in which we respond to epidemics and reaffirms our commitment to head on international public health emergencies wherever they may arise. http://glassdoor.com/slink.htm?key=vQofq
Grifols Diagnostic Solutions featured in the San Francisco Business Times Grifols Diagnostic Solutions was recently featured in a supplement to the SF Business Times! Quoting leadership from the Diagnostic Commercial Division, the article discusses Grifols’ commitment to the Bay Area region, future plans for investment in the Emeryville site and its social impact on the neighboring communities. Click here to read the article: http://glassdoor.com/slink.htm?key=vQOhs
